B of A Securities Upgrades Elevance Health to Buy, Raises Price Target to $435

Benzinga Newsdesk www.benzinga.com Positive 89.9%

Neg 0% Neu 0% Pos 89.9%

B of A Securities analyst Kevin Fischbeck upgrades Elevance Health (NYSE:ELV) from Neutral to Buy and raises the price target from $405 to $435.